Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.73 USD | -5.21% | -9.63% | -37.78% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 488M |
---|---|---|---|---|---|
Net income 2024 * | -134M | Net income 2025 * | -166M | EV / Sales 2024 * | - |
Net cash position 2024 * | 82.2M | Net cash position 2025 * | 129M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.63
x | P/E ratio 2025 * |
-3.35
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.09% |
Latest transcript on Olema Pharmaceuticals, Inc.
1 day | -5.21% | ||
1 week | -9.63% | ||
Current month | -14.16% | ||
1 month | -12.70% | ||
3 months | -35.29% | ||
6 months | -36.51% | ||
Current year | -37.78% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Kushner
FOU | Founder | 86 | 06-08-06 |
Sean Bohen
CEO | Chief Executive Officer | 58 | 20-08-31 |
Cyrus Harmon
FOU | Founder | 54 | 06-08-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Clark
CHM | Chairman | 62 | 20-07-31 |
J. Garland
BRD | Director/Board Member | 55 | 23-10-15 |
Andy Rappaport
BRD | Director/Board Member | 66 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.59% | 4 M€ | -5.15% | - | |
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 8.73 | -5.21% | 626,327 |
24-05-22 | 9.21 | -1.60% | 448,119 |
24-05-21 | 9.36 | -1.68% | 618,063 |
24-05-20 | 9.52 | -3.25% | 516,490 |
24-05-17 | 9.84 | +1.86% | 547,955 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.78% | 488M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+46.17% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- OLMA Stock